Simplifying the CRISPR patent landscape
CRISPR gene-editing technology is advancing, but licensing is complex. A new Merck KGaA, Darmstadt, Germany partnership aims to simplify this path, accelerating research.
We offer products for the use of gene-editing technology known as CRISPR, which enables genome modification. It offers hope in therapeutics, can shorten drug development timelines and can help to treat previously untreatable diseases.
Life Science Tools
Reaching the potential of CRISPR technology
CRISPR-based genomic scissors opens up new possibilities in medicine and biotechnology. Researchers put their trust in life science tools from MilliporeSigma. Learn more
A complex patent and licensing situation
There are more than 18,000 CRISPR patent applications globally. We have 20 in nine countries, and with Broad, offer non-exclusive licenses to respective CRISPR IP portfolios, increasing research availability.
Our expertise in genome-editing technology
Similar to a word processing program, which finds, deletes or replaces words or letters, CRISPR searches for DNA sequences in a cell, cuts them and allows the cell to paste in new DNA information. We have 15 years’ experience in gene editing and are leaders in the field.
Correcting genes that cause disease
Much has transpired in the medical research and biotechnology fields since the first reports of success in deciphering the human genome. Scientists have long been working on identifying genes that are associated with cancer, for example. And now they have a path forward: to specifically modify the sequences of these genes using genomic scissors and learn how they work. The results to date are promising. However, it will still take some time before genome editing can be routinely used in medical therapy.
New paths in disease research
Treating diseases by the repair of gene defects is only one of the possible fields of application for CRISPR technology. It is also used in basic and pharmaceutical research. By knocking out genes, scientists learn what functions these genes have and how diseases develop. Our CRISPR tools are used to create model systems for diseases – systems that provide important new findings for developing and testing novel medicines.
Reliable production of active ingredients
Biopharmaceutical production also benefits from our Life Science portfolio: we offer cell lines for the production of biopharmaceuticals, such as therapeutic antibodies. These cells have been modified by means of genome editing technology in such a way that they are less susceptible to contamination in the bioreactor, thus making the production of active ingredients more reliable and more stable.
Our ZFN and CRISPR portfolio
Our Life Science business offers a wide selection of products for genome editing – for research and production. Please visit our website for more information.
For information about licensing our CRISPR patents, click here.
Work With Us
Our Professionals Make a Difference!
When great minds get together, they inspire each other. Our collaborative culture proves it. By working a better way—sharing ideas, voicing opinions, giving feedback and lending support—we get better results.View All Jobs